Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 8;6(1):66-69.
doi: 10.36519/idcm.2024.295. eCollection 2024 Mar.

Comparison of the i-test COVID-19 Rapid Antigen Test with Real-Time Reverse Transcriptase PCR

Muhammet Çağrı Yıldız  1 , Harun Ağca  1 , Osman Kaya  2 , İlke Selçuk  3 , Pınar Akalın  3 , Emin Halis Akalın  4
Affiliations

Comparison of the i-test COVID-19 Rapid Antigen Test with Real-Time Reverse Transcriptase PCR

Muhammet Çağrı Yıldız et al. Infect Dis Clin Microbiol. .

Abstract

Objective: Improvements in SARS-CoV-2 diagnosis with easy, rapid and cost-effective approaches are required to control the COVID-19 pandemic. Antigen tests result in 5 to 30 minutes, providing an advantage over polymerase chain reaction (PCR) in duration. We tested the performance of the i-test COVID-19 rapid antigen test to real-time reverse transcriptase PCR in 200 symptomatic COVID-19 suspected patients. The cycle threshold (Ct) values of the patients were found to be between 21.6 and 34.4. The Ct value of 10 patients who tested positive in the PCR test was >30. We found that the sensitivity and specificity of the antigen test were 80.6 % and 93.7 %, respectively, for samples with a Ct value of <30, and overall agreement between antigen and PCR test was 91.6 % for these samples. i-test COVID-19 rapid antigen test can be used for screening in schools, factories, nursing homes, and everywhere where PCR test is unavailable.

Keywords: COVID-19; PCR; antigen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Otte Im Kampe E, Lehfeld AS, Buda S, Buchholz U, Haas W. Surveillance of COVID-19 school outbreaks, Germany, March to August 2020. Euro Surveill. 2020;25(38):2001645. doi: 10.2807/1560-7917.ES.2020.25.38.2001645. - DOI - PMC - PubMed
    1. Pollock NR, Jacobs JR, Tran K, Cranston AE, Smith S, O'Kane CY, et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. J Clin Microbiol. 2021;59(5):e00083-21. doi: 10.1128/JCM.00083-21. - DOI - PMC - PubMed
    1. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Geneva: World Health Organization (WHO) [September 28, 2022]. https://www.who.int/publications/i/item/antigen-detection-in-the-diagno...
    1. Krüttgen A, Cornelissen CG, Dreher M, Hornef MW, Imöhl M, Kleines M. Comparison of the SARS-CoV-2 rapid antigen test to the real star SARS-CoV-2 RT PCR kit. J Virol Methods. 2021;288:114024. doi: 10.1016/j.jviromet.2020.114024. - DOI - PMC - PubMed
    1. Krüger LJ, Lindner AK, Gaeddert M, Tobian F, Klein J, Steinke S, et al. A multicenter clinical diagnostic accuracy study of SureStatus, an affordable, WHO emergency use-listed, rapid, point-of-care antigen-detecting diagnostic test for SARS-CoV-2. Microbiol Spectr. 2022;10(5):e0122922. doi: 10.1128/spectrum.01229-22. - DOI - PMC - PubMed

LinkOut - more resources